Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
Launched by CHINESE PLA GENERAL HOSPITAL · Jan 29, 2009
Trial Information
Current as of June 15, 2025
Unknown status
Keywords
ClinConnect Summary
This is a 17 week, randomized, single center, open-label, parallel-group study to compare glucose excursions and other efficacy and safety parameters of repaglinide thrice daily or metformin thrice daily in newly diagnosed type 2 diabetes subjects in China.
Eligibility for participation will be determined by medical history, physical examination, and laboratory results obtained during a screening visit (see trail population). About 60 patients with newly diagnosed (within 6 months) type 2 diabetes and both insulin and oral antidiabetic drugs (OAD) naïve will be include in this study. All s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Informed consent obtained before any trial-related activities. (Trial- related activities are any procedure that would not have been performed during normal management of the subject.)
- • 2. Ages between 20-90 years
- • 3. BMI between 18.5 and 30 kg/m2
- • 4. Newly diagnosed type 2 diabetes. Type 2 diabetes is in accordance with WHO criteria 1999
- • 5. The history of diabetes less than 6 months
- • 6. HbA1c \<10%.
- • 7. Only on diet and/or exercise, OAD or insulin naïve subjects
- Exclusion Criteria:
- • 1. Any history of OAD or insulin therapy preceding this trial.
- • 2. Type 1 diabetic subjects, including LADA
- • 3. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (adequate contraceptive measures are sterilisation, IUD, oral contraceptives or barrier methods) before and/or during the trial.
- • 4. Impaired hepatic function (ALT \> 2.5 times upper limit of local laboratories normal ranges)
- • 5. Impaired renal function, defined as serum creatinine ≥ 1.5 mg/dl.
- • 6. Use of systemic or inhaled glucocorticoids or other medication known to interfere with glucose metabolism.
- • 7. Recently had acute diabetic complications
- • 8. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- • 9. Recently had operation, injury, inflammation and other stress conditions.
- 10. Recently had cardiac disease as following:
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Chunlin Li, M.D&Ph.D
Principal Investigator
PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials